Nitric Oxide Release1. 使用 DMSO 制备 10 mM NOR 储备溶液。 由于 NOR 原液不稳定，请将其放在冰浴上，并在一天内使用。 2． 将适量的 NOR 储备溶液添加到要释放 NO 的样品溶液中。 为避免 DMSO 可能对细胞造成损害，NOR 原液的体积不应超过样品体积的 1/50。 样品溶液应具有足够的缓冲作用。 加入 NOR 储备溶液后，NO 将立即释放。
1. S. Shibata, et al., Characteristics of the Vasorelaxing Action of (3E)-4-Ethyl-2-hydroxyimino-5-nitro-3-hexamide FK409, a New Vasodilator Isolated from Microbial Sources, in Isolated Rabbit Arteries. J Cardiovasc Pharmacol. 1991;17:508-518.2. Y. Kita, et al., Antianginal Effects of FK409, a New Spontaneous NO Releaser. Br J Pharmacol. 1994;113:1137-1140.3. Y. Kita, et al., Antiplatelet Activities of FK409, a New Spontaneous NO Releaser. Br J Pharmacol. 1994;113:385-388.4. Y. Kita, et al., Spontaneous Nitric Oxide Release Accounts for the Potent Pharmacological Actions of FK409. Eur J Pharmacol. 1994;257:123-130.5. M. Hino, et al., FK409, a Novel Vasodilator Isolated from the Acid-treated Fermentation Broth of Streptomyces Griseosporeus I. Taxonomy, Fermentation, Isolation, and Physico-chemical and Biological Characteristics. J Antibiot. 1989; 42:1578-1583.6. J. Decout, et al., Decomposition of FK409, a New Vasodilator: Identification of Nitric Oxide as Metaborite. Bioorg Med Chem Lett. 1995;5:973-978.7. S. Fukuyama, et al., A New Nitric Oxide (NO) Releaser: Spontaneous NO Release from FK409. Free Radic Res. 1995;23:443-452.8. Y. Kita, et al., FR144420, a Novel, Slow, Nitric Oxide-releasing Agent. Eur J Pharmacol. 1995;275:125-130.9. M. Kato, et al., New Reagents for Controlled Release of Nitric Oxide. Structure-stability Relationships. Bioorg Med Chem Lett. 1996;6:33-38.10. Y. Kita, et al., FK409, a Novel Spontaneous NO Releaser: Comparative Pharmacological Studies with ISDN. Cardiovasc Drug Rev. 1996;14:148-165.11. Y. Hirasawa, et al., Antianginal Effects of FR144420, a Novel Nitric Oxide-releasing Agent. Eur J Pharmacol. 1996;303:55-59.12. M. Sato, et al., Nitric Oxide Raises Cytosolic Concentrations of Ca2+ in Cultured Nodose Ganglion Neurons from Rabbits. Neurosci Lett. 1996;206:69-72.13. Y. Kita, et al., Oral Biological Activities of Spontaneous Nitric Oxide Releaser are Accounted for by their Nitric Oxide-releaseing Rates and Oral Absorption Manners. J Pharmacol Exp Ther. 1996;276:421-425.14. S. Fukuyama, et al., Structure-activity Relationships of Spontaneous Nitric Oxide Releasers, FK409 and its Derivatives. J Pharmacol Exp Ther. 1997;282:236-242.15. Y. Kita, et al., Comparison of Hemodynamic Effects of Nitric Oxide (NO) Donors with Different NO-releasing Properties in Rats. J Cardiovasc Pharmacol. 1997;30:223-228.16. Y. Hirasawa, et al., Comparison of Antiplatelet Effect of two Nitric Oxide-donating Agents, FR146801 and FK409. Thromb Haemost. 1998;79:620-624.
How do I prepare a stock solution?
用 DMSO 制备 10-50 mM NOR 溶液。 DMSO 应干燥。 然后向细胞培养物中加入足够的 NOR 溶液，以获得合适浓度的 NOR。
What is the solubility of NOR compounds?
NOR 1: 100 mg per 100 ml DMSO (4.3 M)NOR 3: 137 mg per 100 ml DMSO (6.4 M)NOR 4: 30 mg per 100 ml DMSO (1.0 M)NOR 5: 30 mg per 100 ml DMSO (0.9 M)
Is oral administration possible?
Yes. Please review the article by Kita and colleagues (Eur. J. Pharmacol., 257, 123-130, 1994).
How many NO molecules does each NOR molecule release in physiological conditions? What are the byproducts?
在生理条件下，平均每个 NOR 分子释放 1 到 1.5 个 NO 分子。 不幸的是，NOR副产物的结构仍不清楚。 然而，对于 NO 释放实验，NOR 副产物在正常浓度下没有细胞毒性。